| 2026-06-04 | Label | FDA label revised: APHEXDA (NDA217159) | Regulator FDA drug label register |
| 2026-02-06 | Trial | New trial registered: Motixafortide for MRD Sensitization in AML | Trial register ClinicalTrials.gov |
| 2025-08-03 | Trial | New trial registered: Evaluating Premedication Regimens (Methylprednisolone vs Dexamethasone-based) for the Prevention of Systemic and Injection Site Reactions to Motixaf | Trial register ClinicalTrials.gov |
| 2025-05-21 | Federal Register | Federal Register notice: Product-Specific Guidances; Draft and Revised Draft Guidances for Industry; Availability | Regulator Federal Register |
| 2025-03-21 | Results | Results posted: Study to Investigate the Effect of BL-8040 (Motixafortide) on the QTc Interval in Healthy Subjects | Trial register ClinicalTrials.gov |
| 2024-10-10 | Label | FDA label revised: Aphexda (NDA217159) | Regulator FDA drug label register |
| 2024-09-05 | Results | Results posted: Safety, Tolerability and Efficacy of the BL-8040 and Atezolizumab for Maintenance Treatment in Subjects With Acute Myeloid Leukemia (AML) | Trial register ClinicalTrials.gov |
| 2024-08-09 | Trial | New trial registered: A Pharmacodynamic Study of the Apheresis Product of Multiple Myeloma Patients Undergoing Quad-induction Followed by Motixafortide + G-CSF Mobilizati | Trial register ClinicalTrials.gov |
| 2024-07-23 | Trial | New trial registered: Mobilization of Stem Cells With Motixafortide (BL-8040) in Combination With G-CSF in Multiple Myeloma Patients | Trial register ClinicalTrials.gov |
| 2024-07-17 | Trial | New trial registered: Gene Editing For Sickle Cell Disease | Trial register ClinicalTrials.gov |
| 2024-06-04 | Trial | New trial registered: SCD Stem Cell Mobilization and Apheresis Using Motixafortide | Trial register ClinicalTrials.gov |
| 2022-11-16 | Trial | New trial registered: Motixafortide and Natalizumab to Mobilize CD34+ Hematopoietic Stem Cells for Gene Therapies in Sickle Cell Disease (SCD) | Trial register ClinicalTrials.gov |
| 2022-03-24 | Trial | New trial registered: Study to Investigate the Effect of BL-8040 (Motixafortide) on the QTc Interval in Healthy Subjects | Trial register ClinicalTrials.gov |
| 2020-09-09 | Trial | New trial registered: Chemo4METPANC Combination Chemokine Inhibitor, Immunotherapy, and Chemotherapy in Pancreatic Adenocarcinoma | Trial register ClinicalTrials.gov |
| 2017-05-14 | Trial | New trial registered: Safety, Tolerability and Efficacy of the BL-8040 and Atezolizumab for Maintenance Treatment in Subjects With Acute Myeloid Leukemia (AML) | Trial register ClinicalTrials.gov |